Genetix Biotherapeutics
PrivateLast Round
Buyout/LBO
Jun 2, 2025
Est. Valuation
$45M
Total Funding Raised
$1.66B
Company Overview
Genetix Biotherapeutics is a biotechnology company that researches, develops, and commercializes potentially transformative gene therapies for severe genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genetix Biotherapeutics Comparables
Compare Genetix Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vertex Pharmaceuticals | 86% | |
| CRISPR Therapeutics | 86% | |
| Editas Medicine | 86% |
For institutional investors. Book with your work email.
Genetix Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Buyout/LBO | Jun 2, 2025 | ||||
| Debt | Mar 18, 2024 | ||||
| Follow-on Offering | Dec 19, 2023 | ||||
| Private Placement | Jun 3, 2022 | ||||
| Private Placement | Sep 8, 2021 | ||||
Follow-on Offering | May 18, 2020 |
For institutional investors. Book with your work email.
Genetix Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hercules Capital | Debt |
| Forbion Capital Partners | Series D, Series C, Series A |
| RA Capital Management | Series D |
| BofA Securities | Follow-on Offering |
| ARCH Venture Partners | Series D, Series C |
| California Institute for Regenerative Medicine | Grant |
| Raymond James | Follow-on Offering |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2018
$633M round led by Goldman Sachs and J.P. Morgan.
For institutional investors. Book with your work email.
Genetix Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Genetix Biotherapeutics's valuation, stock price, and market status.
Is Genetix Biotherapeutics a public or private company?
Genetix Biotherapeutics is a private company.
What is the current stock price of Genetix Biotherapeutics?
Genetix Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Genetix Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Genetix Biotherapeutics worth (valuation)?
Genetix Biotherapeutics's valuation is estimated at $45.0M based on funding round data.
Can I buy Genetix Biotherapeutics stock?
Genetix Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Genetix Biotherapeutics's last funding round?
Genetix Biotherapeutics's most recent funding round was Buyout/LBO on June 2, 2025.
Who are the main investors in Genetix Biotherapeutics?
Key investors in Genetix Biotherapeutics include Hercules Capital, BofA Securities, ARCH Venture Partners, California Institute for Regenerative Medicine, Goldman Sachs & Co. LLC.
Will Genetix Biotherapeutics IPO soon?
No public IPO plans have been announced for Genetix Biotherapeutics.
How can I track Genetix Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Genetix Biotherapeutics's shares on secondary markets.